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Increase of inhibitor-2 of protein phosphatase-2A IPP2A2 is associated with protein
phosphatase-2A (PP2A) inhibition and tau hyperphosphorylation in Alzheimer’s disease
(AD). Down-regulating IPP2A2 attenuated amyloidogenesis and improved the cognitive func-
tions in transgenic mice expressing amyloid precursor protein (tg2576). Here, we found that
silencing IPP2A2 by hippocampal infusion of Lenti - siI
PP2A
2 down-regulated I
PP2A
2 (~45%) with
reduction of tau phosphorylation/accumulation, improvement of memory deficits, and den-
dritic plasticity in 12-month-old human tau transgenic mice. Silencing IPP2A2 not only restored
PP2A activity but also inhibited glycogen synthase kinase-3β (GSK-3β) with a significant
activation of protein kinase A (PKA) and Akt. In HEK293/tau and N2a/tau cells, silencing
IPP2A2 by pSUPER - siI
PP2A
2 also significantly reduced tau hyperphosphorylation with restora-
tion of PP2A activity and inhibition of GSK-3β, demonstrated by the decreased GSK-3β
total protein and mRNA levels, and the increased inhibitory phosphorylation of GSK-3β at
serine-9. Furthermore, activation of PKA but not Akt mediated the inhibition of GSK-3β by
IPP2A2 silencing. We conclude that targeting I
PP2A
2 can improve tau pathologies and memory
deficits in human tau transgenic mice, and activation of PKA contributes to GSK-3β inhibi-
tion induced by silencing IPP2A PP2A2 in vitro, suggesting that I2 is a promising multiple target
of AD.
( )
Keywords:Alzheimer disease, inhibitor-2 of protein phosphatase-2A, glycogen synthase kinase-3β, tau hyperphos-
phorylation, memory
INTRODUCTION
Alzheimer’s disease (AD) is the most common neurodegenera-
tive disorder. Neuropathological studies have demonstrated that
formation of neurofibrillary tangles (NFTs) is one of the most
prominent pathologic characteristics in the brain of AD patients,
and the abnormally hyperphosphorylated tau is the major protein
subunit of the tangles (Grundke-Iqbal et al., 1986; Lee et al., 1991).
Though the mechanism leading to the formation of NFTs is still
elusive, it has been well recognized that an imbalanced regulation
in protein kinases and protein phosphatases is the direct cause for
the AD-like tau hyperphosphorylation (Gong et al., 2000; Planel
et al., 2000; Liu et al., 2005; Qian et al., 2010). Among various
kinases and phosphatases, glycogen synthase kinase-3β (GSK-3β;
Avila and Díıaz-Nido, 2004; Takashima, 2006; Hernandez et al.,
2013) and protein phosphatase (PP)-2A (Wang et al., 1995; Gong
Abbreviations: AD, Alzheimer’s disease; GSK-3β, glycogen synthase kinase-3β;
IPP2A1 , PP2A inhibitor 1; I
PP2A
2 , inhibitor-2 of protein phosphatase-2A; NFTs,
neurofibrillary tangles; OA, okadaic acid; PP2A, protein phosphatase-2A; WT,
wortmannin.
et al., 2000; Liu et al., 2005; Rudrabhatla and Pant, 2011) are the
most implicated.
Of the two isoforms of GSK-3, GSK-3α and GSK-3β, GSK-3β is
the major tau kinase (Ishiquro et al., 1993; Takashima et al., 1996)
which can phosphorylate tau at multiple AD-related sites, includ-
ing Ser-46, Thr-50, Thr-175, Thr-181, Ser-199, Ser-202, Thr-205,
Thr-212, Thr-217, Thr-231, Ser-235, Ser-396, Ser-400, Ser-404, and
Ser-413 (Wang and Liu, 2008; Hanger et al., 2009). GSK-3β has
also been directly linked to several key pathological mechanisms
of AD (Lovestone et al., 1994; Hong et al., 1997; Munoz-Montano
et al., 1997; Liu et al., 2003; Cai et al., 2012). In the AD brains,
activated GSK-3β is accumulated not only in a subpopulation
of neurons with NFTs but also in dystrophic neurites of senile
plaques, neuropil threads, Pick bodies, tau-containing astrocytes,
and coiled bodies (Pei et al., 1999; Ferrer et al., 2002). It was also
observed in transfected cells and rat brains that activation of GSK-
3β could efficiently induce tau hyperphosphorylation at most of
the hyperphosphorylated sites seen in the paired helical filaments
(PHFs) isolated from AD brains (Lovestone et al., 1994; Hong
et al., 1997; Liu et al., 2005; Cavallini et al., 2013). Transgenic
mice overexpressing GSK-3β display tau hyperphosphorylation,
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disrupted microtubules, and apoptotic neurons (Lucas et al.,
2001). Therefore, downregulation of GSK-3β could be promising
in arresting AD pathologies.
Protein phosphatase-2A (PP2A) accounts for ~70% of the total
tau phosphatase activity in human brain and the activity of PP2A
is significantly inhibited in the AD brains with concurrent hyper-
phosphorylation of tau (Gong et al., 1993, 1995; Liu et al., 2005).
In vitro and animal studies have demonstrated that inhibition of
PP2A causes tau hyperphosphorylation and the related patholog-
ical alterations, while simultaneous upregulation of PP2A rescues
the pathologies (Wang et al., 1995, 1998, 2007; Gong et al., 2000;
Sun et al., 2003; Tian et al., 2004; Arif et al., 2014). Negative corre-
lation between PP2A activity and the level of tau phosphorylation
at most of the phosphorylation sites in human brains further
supports the dominant role of PP2A in regulation of tau phos-
phorylation as compared with other protein phosphatases (Liu
et al., 2005). Recent studies demonstrate that PP2A is inhibited by
intracellular heat-stable factors namely PP2A inhibitor-2
(
IPP2A2
)
and inhibitor 1 (Li et al., 1995; Tsujio et al., 2005) and activated by
phospho-tyrosyl phosphatase activator (PTPA) (Luo et al., 2013).
In the AD brain, both the transcript and the protein levels of
IPP2A2 are increased (Tanimukai et al.,2005),and the I
PP2A
2 protein is
co-localized with PP2A and the abnormally hyperphosphorylated
tau in the neuronal cytoplasm (Tanimukai et al., 2005). Silencing
IPP2A2 can restore PP2A activity and ameliorate amyloidogenesis in
tg2576 mice (Liu et al., 2013). The human tau transgenic mouse
(htau) is the ideal model for searching the target to inhibit tau
pathologies, however, the effects of IPP2A2 knockdown in this mouse
model has not been studied.
In the present study, we found that silencing IPP2A2 could
improve tau pathologies with improvement of memory deficits
through activation of PP2A and inhibition of GSK-3β in htau mice,
further studies in HEK293/tau and N2a/tau cells demonstrate that
activation of protein kinase A (PKA) but not Akt mediates the
GSK-3β inhibition induced by silencing IPP2A2 .
MATERIALS AND METHODS
ANTIBODIES AND CONSTRUCTION OF PLASMIDS
The detailed information for the antibodies used in this work
is listed in Table S1 in Supplementary Material. Rp-adenosine
3′, 5′-cyclic monophosphorothioate triethyl ammonium salt (Rp-
cAMPS, a specific inhibitor of PKA) and okadaic acid (OA) were
purchased from Sigma. To knockdown IPP2A2 in cells, shRNA oligo
sequences were synthesized as follow: 5′-AGCTTGGATGAAGGT
GAAGAAGATTTCAAGAGAATCTTCTTCACCTTCATCCTTTT
TC-3′, 5′-TCGAGAAAAA GGATGAAGGTGAAGAAGATTCTCT
TGAAATCTTCTTCACCTTCATCCA-3′. As control, we used non-
functional IPP2A2 -derived sequences: 5
′-AGCTTTGAGAGTGGT
GATCCATCTTTCAAGAGAAGATGGATCACCACTCTCATTTT
TC-3′, 5′-TCGAGAAAAATGAGAGTGGTGATCCATCTTCTCTT
GAAAGATGGATCACCACTCTCAA-3′ (ten Klooster et al., 2007;
Liu et al., 2008). All were purchased as 63-nt ssDNA oligomers
composed of both forward and reverse sequences with 9-bp
loop structures (Brummelkamp et al., 2002) and 3′ Xho1 I
and 5′ HindIII self-inactivating overhangs. Sense and anti-
sense oligomers (both at 20µM) were incubated in annealing
buffer for 3 min at 90°C as described (Elbashir et al., 2001),
then the temperature was lowered in 2°C/min increments until
5°C above their respective T m and then dropped to 4°C at
maximum ramp rates. pSUPER, a mammalian expression vec-
tor that directs the synthesis of siRNAs (Brummelkamp et al.,
2002) was digested with both Xhol I and HindIII. Annealing
shRNA was cloned into Xhol I and HindIII-digested pSUPER
(pSUP): pSUPER - siIPP2A2
(
pSUP - siIPP2A2
)
and pSUPER-siCon
(pSUP-siC).
PRODUCTION OF LENTIVIRAL VECTORS
Vector plasmids were constructed for the production of third-
generation lentivirus-expressing siRNA for IPP2A2 . Fortunately, the
siRNA target for human IPP2A2 also paired with the sequence
of mouse IPP2A2 and knockdown I
PP2A
2 level in N2a cells. All
vectors contained the eGFP coding sequence located in the
middle of the lentiviral vector. This sequence is driven by a
cytomegalovirus (CMV) promoter and terminates using the
polyadenylation signal in the 3′ long terminal repeat (LTR). Down-
stream of the eGFP is a woodchuck hepatitis virus regulatory
element (WPRE) that enhances the expression of the transgene.
Recombinant lentiviruses were produced by transient transfec-
tion in HEK293T cells using the calcium phosphate transfection
method, as described previously (Naldini et al., 1996). The infec-
tious lentiviruses were harvested at 48 and 72 h post-transfection
and filtered through 0.22-µm-pore cellulose acetate filter. The
infectious lentiviruses were concentrated by ultracentrifugation
(2 h at 50,000× g ) and subsequently purified by ultracentrifu-
gation on a 20% sucrose gradient (2 h at 46,000× g ) as described
(Naldini et al., 1996).Vector concentrations were analyzed using an
immunocapture p24-gag ELISA (Alliance; DuPont-NEN; Naldini
et al., 1996) and by flow cytometry quantification of eGFP-positive
transduced cells, as described previously (Marr et al., 2003).
BRAIN INJECTION OF LENTI - siIPP2A2
The human tau transgenic mice (htau, ~11-month-old) [STOCK
Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/J, Jackson Lab], which express
six isoforms of tau and show an age-dependent development tau
pathology and impairments of cognitive and synaptic functions
(Polydoro et al., 2009) were used for the study. For brain injec-
tions, the mice were positioned in a stereotaxic instrument and
2µl Lenti - siIPP2A2 or Lenti - ssiI
PP2A
2 were injected into the hip-
pocampus (AP – 2.0, ML – 1.5, DV – 2.0; Kaspar et al., 2002)
at a rate of 0.50µl/min. The syringe was left in the place for
~3 min before being slowly withdrawn from the brain. After
4 weeks, the mice were sacrificed, and the hippocampi were quickly
removed out and homogenized on ice in lysis buffer [50 mM
Tris–HCl (pH 7.5), 150 mM NaCl, 1% (v/v) Triton X-100, 1%
(w/v) deoxycholate, 0.1% (w/v) SDS, 10 mM NaF, 1 mM Na3VO4,
and 2µg/ml each of aprotinin, leupeptin, and pepstatin A], then
brain extracts stored in −80°C. All mice were kept at 24± 2°C
on daily 12 h light–dark cycles with ad libitum access to food and
water. The animal experiments were carried out according to the
“Policies on the Use of Animals and Humans in Neuroscience
Research” approved by the Society for Neuroscience in 1995, and
also approved by Institutional Animal Care and Use Committee
at Tongji Medical College, Huazhong University of Science and
Technology.
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STEP-DOWN AVOIDANCE TEST
Four weeks after the brain infusion of the lentiviral vectors, the
step-down avoidance test was performed by following a previous
procedure (Zarrindast et al., 2006). Briefly, the apparatus consisted
of an open field gray Plexiglas box (40 cm× 40 cm) with a steel
rod floor. The Plexiglas platform (4 cm× 4 cm× 4 cm) was set in
the center of the grid floor. Intermittent electric shocks (20 mA,
50 Hz) were delivered to the grid floor by an isolated stimulator.
On the first day, each mouse was gently placed on the platform.
When the mouse stepped down from the platform and placed
all its paws on the grid floor, an intermittent electric shock was
delivered for 3 s. Responsiveness to the punishment in the train-
ing test was assessed by the animal’s vocalization, only those mice
that vocalized touching the grid with the four paws were used for
the retention test in order to exclude the mice with a different
pain threshold. Two hours [short-term memory (STM)] or 24 h
[(long-memory (LTM)] after training, each mouse was placed on
the platform again. The first time spent before stepping down onto
the grid (latency period) and frequency (number of errors) step-
ping down the platform were measured, considering 300 s as the
upper cut-off, during the training and retention tests.
CELL CULTURE AND TRANSIENT EXPRESSION
The human embryonic kidney 293 cells or mouse N2a neurob-
lastoma cells stably expressing the longest human tau (tau441)
cDNA (HEK293/tau or N2a/tau) were cultured in DMEM sup-
plemented with 10% fetal bovine serum (FBS). The cells were
maintained at 37°C in 5% CO2. The cells were plated onto six-well
plates overnight and pSUP, pSUP-siC, or pSUP - siIPP2A2 plasmid
was transfected the next day using Lipofectamine 2000 according
to the manufacturer’s instruction.
ACTIVITY ASSAY OF PROTEIN KINASES PP2A
The cells were transfected with pSUP, pSUP-siC, or pSUP - siIPP2A2
plasmids. After 24 h, the cell lysate was prepared by adding
lysis buffer [20 mM MOPS, 50 mM β-glycerophosphate, 50 mM
sodium fluoride, 1 mM sodium vanadate, 5 mM EGTA, 2 mM
EDTA, 1% NP40, 1 mM dithiothreitol (DTT), 1 mM benzamidine,
1 mM phenylmethanesulfonyl fluoride (PMSF), and 10µg/ml leu-
peptin and aprotinin, pH 7.2]. The activity of PKA in the extract
was assayed using a PKA kinase activity assay kit (Assay Designs,
Inc.,) according to the manufacturer’s protocol.
The activity of PP2A was assayed using a serine/threonine
phosphatase assay kit (Promega, MA, USA). The assay was based
on determining the amount of free phosphate generated in the
reaction by measuring the absorbance of a molybdate malachite
green–phosphate complex. Cell extracts were prepared as follows:
cells were rinsed twice with ice-cold phosphate-buffered saline and
then scraped into 1 ml of ice-cold phosphatase buffer [50 mM Tris,
pH 7.0, 0.1 mM ethylenediaminetetraacetic acid/ethylene glycol-
bis(β-aminoethyl ether)-N,N,N ′,N ′-tetraacetic acid, 1 mM DTT,
0.1% (v/v) Triton X-100, benzamide, leupeptin, 4-(2-aminoethyl)
benzene-sulfonyl fluoride·HCl (AEBSF), and pepstatin A]. The
resulting cell suspension was lysed by brief sonication and cell
debris were pelleted at 15,000× g for 30 min. Free intracellular
phosphate and ATP were removed from this resulting supernatant
in a spin column containing Sephadex G-25 according to the
supplier’s instructions. The sample (10µg) was incubated on a
96-well plate together with a peptide substrate RRA(pT)VA and
PP2A-specific reaction buffer (50 mM imidazole, pH 7.2, 0.2 mM
EGTA, 0.02% β-mercaptoethanol, 0.1 mg/ml BSA) for 30 min at
30°C. After incubation, the molybdate complex dye was added and
incubated for an additional 30 min at room temperature for color
development. The level of molybdate malachite green–phosphate
complex formed was monitored at 630 nm.
GOLGI STAINING
Golgi staining was performed according to methods as followed
(Woolley and McEwen, 1992). The mice (n= 3 per group) were
killed by overdose of chloral hydrate, and perfused through the
aorta with 200 ml 0.9% NaCl containing 0.5% sodium nitrite fol-
lowed by 500 ml 0.9% NaCl containing 5% formaldehyde. Then,
the brain was fixed in situ by perfusion of Golgi fixative (0.9%
NaCl, 5% formaldehyde, 5% potassium dichromate, 5% chloral
hydrate) in the dark. The brain was removed and processed for
rapid Golgi staining in the dark. Briefly, the brain was post-fixed for
3 days in the same Golgi fixative, and impregnated with 1.0% aque-
ous silver nitrate solution for 3 days. Coronal brain sections of hip-
pocampal tissue were cut at 35µm using a vibratome (VT1000S,
Leica, Germany). The images were observed by using a micro-
scope (Olympus BX60, Tokyo, Japan). Neurons in the CA3 region
which fulfill the following criteria were selected for the analysis; (i)
the cell type must be identifiable, (ii) image resolution should be
sufficient to visually distinguish dendritic spine formation from
variably contrasting background, and (iii) completeness of Golgi
impregnation of all dendrites. Subjective bias in spine counting
was eliminated by prior coding of slides.
To analyze the dendritic morphology, Z -stacks (step size 1µm)
from five to seven cells were generated using a confocal micro-
scope (LSM510, Zeiss) in bright-field mode (20× objective) and
reconstructed in ImagePro in combination with the NeuroDraw
toolbox for each animal. Total dendritic length and number of
branch points were analyzed using NeuroExplorer software (MBF
Bioscience, Williston, VT, USA).
To acquire images for spine analysis, the dendritic segments
were imaged under bright-field illumination on a Zeiss Axio
imager microscope with a 63× oil immersion objective, and spine
morphology was analyzed according to a previously reported
method (Magarinos et al., 2011), which does not assess spine den-
sity in a three dimensional manner but focuses on spines paralleled
to the plane of section. Although the method may underestimate
the total number of spines, it facilitates a direct comparison of
treatment groups when they are analyzed in an identical man-
ner. ImageJ software was used to calculate linear spine density
(Spires-Jones et al., 2011), which was presented as the number of
spines per 10 mm of dendrite length. The spine density was deter-
mined in two segments of dendrites at a distance of 90–110µm
(proximal) and 190–210µm (distal) from the soma. From each
animal, four neurons were selected from one slide, accounting for
36 neurons/per animal.
REAL-TIME PCR
Total RNA was isolated by using Trizol™(Invitrogen Life Tech-
nologies, Carlsbad, CA, USA) according to manufacturer’s
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instruction. Then total RNA (3µg in 25µl) was reversely tran-
scribed and the produced cDNA (1µl) was used to detect
the transcripts. Real-time polymerase chain reaction (PCR)
to determine gene copy number was performed using the
Rotor-Gene 3000 Real-Time PCR Detection System (Corbett
Research, Sydney, NSW, Australia) with the SYBR® Premix Ex
Taq™[Takara Biotechnology (Dalian) Co., Ltd., Dalian, China].
The expression level of GADPH housekeeping gene was used
for normalization of GSK-3β mRNA expression level. Forward
primer 5′-ACGCTCCCTGTGATTTATG-3′ and reverse primer
5′-CAAGAGGTTCTGCGGTTTA-3′ for GSK-3β; forward primer
5′-CTTCAACTCTGGTCAAATAATGCA-3′ and reverse primer
5′-GAACAAAAATATAACAAACTCCGC-3′ for IPP2A2 ; forward
primer 5′-GAAGGTGAAGGTCGGAGTC-3′ and reverse primer
5′-GAAGATGGTGATGGGATTTC-3′ for GADPH.
WESTERN BLOTTING
Western blotting was performed according to methods established
in our laboratory. Briefly, the cell homogenates or brain extracts
were mixed with sample buffer containing 50 mM Tris–HCl (pH
7.6), 2% SDS, 10% glycerol, 10 mM DTT, and 0.2% bromophe-
nol blue and boiled for 5 min. The proteins were separated by
10% SDS/PAGE and transferred to PVDF membrane. Immunos-
taining was visualized with a chemiluminescent substrate kit and
CL-XPosure Film and quantitatively analyzed by digital science
1D software (Eastman Kodak, Rochester, NY, USA). Band inten-
sity was measured as the sum optical density and expressed as a
level relative to each control. The phosphorylated levels of tau were
normalized relative to the total tau.
IMMUNOFLUORESCENCE STAINING
The transgenic mice were sacrificed by overdose chloral hydrate
(1 g/kg) after injection of lentiviral vectors for about 1 month,
FIGURE 1 | Expression of Lenti - siIPP2A2 decreases I
PP2A
2 level in htau
mice. (A) IPP2A2 (I2) protein in the hippocampus of the ~11-month-old htau
mice or the age-control wild-type (wt) mice was detected by Western
blotting. (B) Approximately 11-month-old htau mice received brain infusion
of the Lenti - siIPP2A2 (Lenti-siI2) or the scrambled Lenti - ssiI
PP2A
2 (Lenti-ssiI2;
2µl each, 2×109 TU/ml) into the hippocampal CA3 region under a
stereotaxic instrument as described in the Section “Materials and
Methods.” Four weeks later, the expression levels of IPP2A2 were detected by
Western blotting and quantitative analysis. (C)The expression of the
lentivirus in CA3 region was presented. The eGFP was stained in the cell
body and dendrites of neurons. L, lateral; M, medial; sl, stratum lucidum;
so, stratum oriens; sp, stratum pyramidale. The data were presented as
mean±SD of three independent experiments. **p<0.01 vs. wt mice or
Lenti-ssiI2/htau2 (htau mice infused with Lenti-ssiI2). Scale bar: 20µm.
and perfused through aorta with 100 ml 0.9% NaCl followed
by 400 ml phosphate buffer containing 4% paraformaldehyde.
Brains were removed and post-fixed in perfusate overnight and
then cut into sections (20µm) with a vibratome (Leica, Nus-
sloch, Germany; S100, TPI). Sections were incubated at 4°C
overnight with primary antibodies (see Table S1 in Supplemen-
tary Material and Figure legends). The images were observed using
FIGURE 2 | Expression of Lenti - siIPP2A2 arrests tau pathology in htau
mice. Approximately 11-month-old htau mice received brain infusion of the
Lenti - siIPP2A2 (Lenti-siI2) or the scrambled Lenti - ssiI
PP2A
2 (Lenti-ssiI2; 2µl
each, 2× 109 TU/ml) into the hippocampal CA3 region under a stereotaxic
instrument as described in the Section “Materials and Methods.” Four
weeks later, the expression level of tau phosphorylation at several
AD-related sites was detected by Western blotting (A,B) and
immunohistochemistry (C). The silver staining images were represented.
(D) L, lateral; M, medial; sl, stratum lucidum; so, stratum oriens; sp,
stratum pyramidale. The data were presented as mean±SD of three
independent experiments. *p<0.05; **p< 0.01 vs. Lenti-ssiI2/htau2 (htau
mice infused with Lenti-ssiI2). Scale bars: 100µm.
FIGURE 3 | Expression of Lenti - siIPP2A2 improves cognitive functions in
htau mice. Approximately 11-month-old htau mice received brain infusion
of the Lenti - siIPP2A2 (Lenti-siI2) or the scrambled Lenti - ssiI
PP2A
2 (Lenti-ssiI2;
2µl each, 2×109 TU/ml) into the hippocampal CA3 region under a
stereotaxic instrument. Four weeks later, the associative short-term
memory (STM) (A) and long-term memory (LTM) (B) were detected by
step-down avoidance test (n=8–10 for each group). The data were
expressed as mean±SD. *p<0.05; **p<0.01 vs. Lenti-ssiI2/htau (htau
mice infused with Lenti-ssiI2).
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FIGURE 4 | Expression of Lenti - siIPP2A2 remodels the dendrite complexity
in htau mice. Approximately 11-month-old htau mice received brain infusion
of the Lenti - siIPP2A2 (Lenti-siI2) or the scrambled Lenti - ssiI
PP2A
2 (Lenti-ssiI2; 2µl
each, 2×109 TU/ml) into the hippocampal CA3 region under a stereotaxic
instrument. Four weeks later (A–D), representative Golgi stained hippocampal
CA3 neurons with its corresponding morphological drawings (A) and
quantitative analysis of the total dendrite length (B), the number of dendritic
branch (C), and the density of dendritic spines (D). So, stratum oriens; sp,
stratum pyramidale. The data were expressed as mean±SD. *p<0.05;
**p<0.01 vs. Lenti-ssiI2/htau (htau mice infused with Lenti-ssiI2).
FIGURE 5 | Expression of Lenti - siIPP2A2 restores PP2A activity with
inhibition of GSK-3 in htau mice. Approximately 11-month-old htau mice
were treated as Figure 1. (A)The activity of PP2A was measured by a PP2A
activity assay kit as described in the Section “Materials and Methods.”
(B–D)The protein levels of the Ser9-phosphorylated GSK-3β (pS9) and total
GSK-3β (tGSK-3β) (B), the levels of phosphorylated Akt at Ser473 (pS473-Akt)
and total Akt (C), and the levels of PKAα, PKAIβ, and PKAIIα (D) were
measured by Western blotting and quantitative analysis. The data were
presented as mean±SD of three independent experiments. *p<0.05;
**p<0.01 vs. Lenti-ssiI2/htau2 (htau mice infused with Lenti-ssiI2).
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a laser scanning confocal microscope (Olympus FV500, Tokyo,
Japan).
For cell studies, cells were cultured on coverslips and fixed with
4% paraformaldehyde for 1.5 h at 4°C and then incubated for
12–36 h at 4°C with primary antibodies overnight as indicated in
each figure,and the immunoreactivity was probed with rhodamine
red X- or Oregon green 488-conjugated secondary antibodies (see
Table S1 in Supplementary Material).
STATISTICAL ANALYSIS
The data were expressed as mean± SD and analyzed by the one-
way analysis of variance procedure followed by least significant
difference post hoc tests or Student’s t -tests for three groups, and
Student’s t -test for two groups using SPSS 12.0 statistical software
(SPSS Inc., Chicago, IL, USA). A p value of <0.05 was considered
as statistically significant in all experiments.
RESULTS
SILENCING IPP2A2 ATTENUATES tau HYPERPHOSPHORYLATION WITH
IMPROVEMENT OF MEMORY DEFICITS IN htau TRANSGENIC MICE
The transcription and expression of IPP2A2 is significantly increased
in the AD brains (Tanimukai et al., 2005), and increasing IPP2A2 by
AAV transfection in rat brain induced AD-like pathology and cog-
nitive impairment (Wang et al., 2010). We found that IPP2A2 protein
level was significantly increased in htau transgenic mice compared
with the wild-type mice (Figure 1A), while intracranial injection
of Lenti - siIPP2A2 into the hippocampus of htau transgenic mice,
a recognized AD-like animal model for tau pathology (Polydoro
et al., 2009), reduced the IPP2A2 level to ~45% of the control level at
4 weeks after the injection (Figure 1B). Simultaneously, the phos-
phorylation level of tau at Thr-205 (pT205), Thr-231 (pT231),
Ser-396 (pS396), and Ser-396/404 (PHF-1) epitopes was signif-
icantly reduced compared with the htau mice injected with the
scrambled Lenti - siIPP2A2 controls (Figures 2A–C). By silver stain-
ing, we observed that the accumulation of argyrophilic substances
was also significantly decreased by expression of Lenti - siIPP2A2
(Figure 2D).
A previous study has demonstrated that the htau transgenic
mice show learning and memory deficits at 12 months (Polydoro
et al., 2009). By step-down avoidance test, we observed that silenc-
ing IPP2A2 improved both the STM and the LTM (Figure 3). These
data demonstrate that silencing IPP2A2 by Lenti - siI
PP2A
2 could
antagonize tau pathology and memory deficits in htau transgenic
mice.
SILENCING IPP2A2 AMELIORATES DENDRITE COMPLEXITY AND SPINE
DENSITY IN htau MICE
To explore the molecular bases underlying the improved mem-
ory by silencing IPP2A2 , we analyzed the dendritic morphology and
spine density of the neurons in hippocampal CA3 region of the
htau transgenic mice using Golgi stain. The dendritic length and
the number of branches were assessed as a measure of dendritic
complexity. We found that silencing IPP2A2 increased the dendritic
length, the number of branches, and the density of the den-
dritic spines (Figure 4), suggesting that silencing IPP2A2 promotes
dendritogenesis.
SILENCING IPP2A2 INHIBITS GSK-3βWITH ACTIVATION OF PKA AND Akt
IN htau TRANSGENIC MICE
Inhibitor-2 of protein phosphatase-2A was originally identified
to regulate PP2A (Li et al., 1995, 1996), therefore we first mea-
sured PP2A activity after silencing IPP2A2 . As expected, silencing
IPP2A2 significantly increased PP2A activity (Figure 5A). Our recent
data show that knockdown of IPP2A2 decreases GSK-3β protein
level in HEK293 cell lines (Liu et al., 2012), the most implicated
tau kinase (Ishiquro et al., 1993; Takashima et al., 1996; Avila
and Díıaz-Nido, 2004; Takashima, 2006), and thus we also mea-
sured the alteration of GSK-3β in hippocampus of the mice after
silencing IPP2A2 . We observed that silencing I
PP2A
2 could inhibit
GSK-3β, demonstrated by the reduced total level of GSK-3β
(tGSK-3β) and elevation of Ser9-phosphorylated GSK-3β (pS9-
GSK-3β; Figure 5B). To further explore how GSK-3β activity is
regulated, we measured the alteration of Akt and PKA, the known
kinases regulating Ser9 phosphorylation of GSK-3β (Cross et al.,
1995; Shaw et al., 1997; Fang et al., 2000). We found that silencing
IPP2A2 activated Akt with increased levels of phosphorylated Akt
at Ser473 epitope and total Akt, and PKA with increased levels
of PKAα (catalytic subunit) and PKAIIα (regulatory subunit) and
decreased PKAIβ (regulatory subunit) level in the hippocampus
(Figures 5C,D).
FIGURE 6 | SiIPP2A2 decreases the expression of I
PP2A
2 and increases PP2A
activity in cell lines. pSUP - siIPP2A2 (pSUP-siI2) was transfected into
HEK293/tau or N2a/tau cells to knockdown the expression of IPP2A2 , pSUP,
and pSUP-siC were transfected as the controls. After 24 h, the level of IPP2A2
in the cell extracts was estimated by Western blotting (A,D) and
immunostaining (B). The activity of PP2A was measured by a PP2A activity
assay kit as described in the Section “Materials and Methods” (C,E). The
relative intensity was normalized against DM1A (to α-tubulin) and
expressed by setting pSUP as 1. The data were presented as mean±SD of
at least three independent experiments. **p<0.01 vs. pSUP.
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FIGURE 7 | Knockdown IPP2A2 phosphorylates GSK-3β at Ser9 and
inhibits GSK-3β activity. HEK293/tau or N2a/tau cells were transfected
with pSUP - siIPP2A2 (pSUP-siI2) for 24 h, and pSUP and pSUP-siC were
transfected as the controls. (A,C)The protein levels of total (tGSK-3β)
and the Ser9-phosphorylated GSK-3β (pS9, the inactive form) were
estimated by Western blotting normalized against DM1A. (B)The mRNA
level of GSK-3β was analyzed by real-time PCR, normalized against
GADPH and expressed by setting pSUP as 1. The data were presented
as mean±SD of three independent experiments. *p<0.05; **p<0.01
vs. pSUP.
SILENCING IPP2A2 INHIBITS GSK-3β THROUGH ACTIVATION OF PKA BUT
NOT Akt DEMONSTRATED IN HEK293/tau OR N2a/tau CELLS
To further verify the role of IPP2A2 silencing in the regulation
of GSK-3β, we constructed pSUP - siIPP2A2 and transfected the
plasmid into HEK293/tau or N2a/tau cells with pSUP (empty
vector) and pSUP-siC (control vector of siRNA) as controls. As
observed in htau transgenic mice, silencing IPP2A2 significantly
decreased the IPP2A2 level in HEK293/tau cells (Figures 6A,B) and
N2a/tau cells (Figure 6D). Simultaneously, the activity of PP2A
was restored after IPP2A2 knockdown in HEK293/tau and N2a/tau
cells (Figures 6C,E). IPP2A2 knockdown also down-regulated GSK-
3β, demonstrated by the reduction of total GSK-3β (tGSK-3β)
protein and mRNA levels, and elevation of the pS9-GSK-3β (the
inactive form) in HEK293/tau cells (Figures 7A,B) and N2a/tau
cells (Figure 7C). These in vitro data further confirm that silencing
IPP2A2 not only activates PP2A but also inhibits GSK-3β.
Akt and PKA are known kinases to regulate Ser9 phosphoryla-
tion of GSK-3β (Cross et al., 1995; Shaw et al., 1997; Fang et al.,
2000). Therefore, we studied the role of Akt and PKA in phospho-
rylating (inhibiting) pS9-GSK-3β. We found unexpectedly that
the total Akt level and the phosphorylated Akt at Thr308 and
Ser473 (active form) decreased by silencing IPP2A2 (Figures 8A,B),
suggesting that Akt activity was decreased by IPP2A2 knockdown.
These data ruled out the role of Akt in phosphorylating GSK-
3β during IPP2A2 knockdown. However, the catalytic subunit α
(PKAα) and the regulatory subunit IIα (PKAIIα) of PKA increased,
whereas the regulatory subunit Iβ (PKAIβ) of PKA decreased after
silencing IPP2A2 in HEK293/tau cells (Figures 8A,B). It is known
that PKA is activated when the catalytic subunit is released from
the tetrameric holoenzyme, which is modulated by the binding
capacity of catalytic subunit to the regulatory subunits. Therefore,
we measured the interactions of PKAα with its regulatory sub-
units by co-immunoprecipitation assay. The results showed that
the association level of PKAα with PKAIβ decreased, whereas the
binding of PKAα with PKAIIα was not altered after IPP2A2 knock-
down (Figure 8C). To confirm the alteration of PKA activity, we
used ELISA assay, and a significantly increased PKA activity was
detected by IPP2A2 knockdown (Figure 8D). These data indicate
that silencing IPP2A2 can also activate PKA.
To further verify the role of PKA in GSK-3β inhibition induced
by silencing IPP2A2 , we used Rp-cAMPS, a specific inhibitor of PKA,
after transfection of siIPP2A2 . We found that simultaneous appli-
cation of Rp-cAMPS abolished the siI
PP2A
2 -induced inhibitory
phosphorylation of GSK-3β at Ser9 (Figure 8E).
We also studied whether silencing siIPP2A2 could attenuate tau
hyperphosphorylation induced by OA (PP2A inhibitor) in vitro.
We transfected pSUP - siIPP2A2 into HEK293/tau or N2a/tau cells,
and treated the cells with OA (25 nM) for 24 h. Then, we detected
tau phosphorylation by Western blotting. We found that silenc-
ing IPP2A2 significantly reduced tau phosphorylation at Ser-199
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FIGURE 8 | Activation of PKA is responsible for the phosphorylation of
GSK-3β at Ser9 induced by IPP2A2 knockdown. HEK293/tau cells were
transfected with pSUP - siIPP2A2 (pSUP-siI2) for 24 h, and pSUP and pSUP-siC
were expressed as the controls. (A,B)The levels of phosphorylated Akt at
Thr308, Ser 473, total Akt, PKAα, PKAIIα, and PKAIβ were estimated by
Western blotting (A) and quantitative analysis (B). (C)The cell lysates were
subjected to immunoprecipitation (IP) with anti-PKAα antibody, and the
precipitates were probed by anti-PKAα, anti-PKAIβ, or anti-PKAIIα. (D)The
activity of PKA was also measured by a PKA assay kit as described in the
Section “Materials and Methods.” (E)The cells with overexpression of
pSUP-siI2, pSUP-siC, or the vector were treated with Rp-cAMPS (Rp, 10µM)
for 30 min, and then pS9-GSK-3β was detected by Western blotting and
quantitative analysis. The relative intensity was normalized against DM1A and
expressed by setting pSUP as 1. The data were presented as mean±SD of
three independent experiments. *p<0.05;**p<0.01 vs. pSUP; #p<0.05 vs.
pSUP-siI2.
(pS199), Thr-205 (pT205), Ser-214 (pS214), Ser231 (pS231), Ser-
396 (pS396), and Ser-404 (pS404), and increased the level of
the unphosphorylated tau at Ser-198/202 (tau-1) induced by OA
in HEK293/tau (Figures 9A,B). The immunofluorescence data
confirmed the same results (Figure 9C). We also found that knock-
down IPP2A2 significantly decreased tau phosphorylation induced
by OA in N2a/tau cells (Figure 9D).
DISCUSSION
As the name designated, IPP2A2 was originally identified as endoge-
nous protein inhibitor of PP2A. We noticed in a recent study that
IPP2A2 may also regulate GSK-3 (Liu et al., 2012). In the present
study, we demonstrated that knockdown IPP2A2 could inhibit GSK-
3 activity by decreasing the levels of GSK-3β mRNA and protein
with an increased inhibitory phosphorylation of GSK-3β at Ser9
in HEK293/tau and N2a/tau cells, and htau transgenic mice. Our
data provide the first evidence that knockdown IPP2A2 not only
restitutes PP2A, but also inhibits GSK-3β.
Glycogen synthase kinase-3β is the downstream of Akt signaling
pathway and its N-terminal serine-9 residue can be phosphory-
lated by Akt (Cross et al., 1995; Shaw et al., 1997; Zhou et al.,
2013). To explore the kinase(s) that may be responsible for the
increased phosphorylation of GSK-3 at Ser9 by IPP2A2 knockdown,
we firstly detected the activity of Akt. We observed that the Akt
activity was decreased in HEK293/tau cell lines; however Akt activ-
ity increased in htau transgenic mice after IPP2A2 knockdown. The
mechanism underlying this discrepancy is currently not under-
stood. It is possible that in native neurons more signal transduction
pathways are active compared to cell lines. Recent studies suggest
that PKA can also phosphorylate and inactivate GSK-3β (Fang
et al., 2000; Zhou et al., 2013), therefore, we detected the activity
of PKA. We found that PKA was activated by IPP2A2 knockdown,
whereas simultaneous inhibition of PKA by Rp-cAMPs abolished
the IPP2A2 knockdown-induced GSK-3β phosphorylation, suggest-
ing that IPP2A2 knockdown may inhibit GSK-3β via activating PKA.
The holoenzyme of PKA is composed of catalytic subunit of PKAα,
Frontiers in Aging Neuroscience www.frontiersin.org June 2014 | Volume 6 | Article 123 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zhang et al. Silencing IPP2A2 rescues tau pathologies
FIGURE 9 | siIPP2A2 attenuates tau hyperphosphorylation induced by
okadaic acid in HEK293/tau or N2a/tau cells. pSUP - siIPP2A2 (pSUP-siI2)
was transfected into HEK293/tau (A–C) or N2a/tau cells (D) to knockdown
the expression of IPP2A2 , and pSUP and pSUP-siC were expressed as the
controls. After 24 h, OA (okadaic acid, 25 nM) was administered for 24 h.
(A,B)The relative levels of hyperphosphorylated tau at Ser-199 (pS199),
Ser-198/202 (tau-1), Thr-205 (pT205), Ser-214 (pS214), Thr-231 (pT231),
Ser-396 (pS396), and Ser-404 (pS404) epitopes were detected by Western
blotting (A) and quantitative analysis (B). (C)The phosphorylated levels of
tau at Ser-198/202 (tau-1), Ser-396, and Ser-404 epitopes were detected by
immunofluorescence staining. (D)The relative levels of
hyperphosphorylation tau at Ser-198/202 (tau-1) and Ser-396 (pS396)
epitopes were detected by Western blotting and quantitative analysis. The
relative intensity was normalized against total tau probed by R134d or tau-5
and expressed by setting pSUP as 1. DM1A serves as a loading control. The
data were presented as mean±SD of at least three independent
experiments. *p<0.05; **p<0.01 vs. pSUP; #p<0.05; ##p<0.01 vs.
pSUP+OA.
and regulatory subunits PKAIIα and PKAIβ, and association of
PKAα with PKAIIα and PKAIβ inhibits the activity of kinase.
Therefore, we detected the expression levels of PKAα, PKAIIα,
and PKAIβ and their interactions. Although IPP2A2 knockdown
increased PKAIIα level that should be inhibitory, the association
of PKAα with PKAIIα or PKAIβ was decreased, which supports
the activation of PKA activity by IPP2A2 knockdown. Based on our
findings, Akt seems not responsible for the in vitro GSK-3β inhi-
bition in the cell lines, however, the in vivo role of Akt in GSK-3β
inhibition may be relatively more important than PKA.
Several groups have reported that GSK-3β seems essential for
cognitive function using genetically engineered mouse models. For
instance, long-term potentiation inhibits the induction of long-
term depression via activation of the PI3K–Akt–GSK-3β pathway
(Peineau et al., 2007; Bradley et al., 2012), and heterozygote GSK-
3β knockout mice show an impaired long-term memory forma-
tion and reconsolidation (Kimura et al., 2008). GSK-3β activities
were far lower than normal levels in these studies. Increased GSK-
3 activity is believed to play a key role in the pathogenesis of CNS
chronic disorders such as AD and schizophrenia (Emamian et al.,
2004; Engel et al., 2006). In AD, there are studies supporting GSK-
3 activity increased (Hye et al., 2005; Leroy et al., 2007), and the
activated GSK-3β is accumulated in a subpopulation of neurons
with NFTs in the AD brains (Pei et al., 1999). GSK-3β was the
first identified tau kinase, which can phosphorylate tau at most
of the hyperphosphorylated sites seen in the PHFs isolated from
AD brains (Lovestone et al., 1994; Hong et al., 1997; Lucas et al.,
2001; Hernandez et al., 2013). In addition to phosphorylate tau,
GSK-3β has been linked to all of the primary abnormalities asso-
ciated with AD. These include interactions between GSK-3β and
components of the plaque-producing amyloid system (Takashima
et al., 1993; Aplin et al., 1996), and interactions of GSK-3β with
presenilin (Takashima et al., 1998; Gantier et al., 2000; Dolma et al.,
2014) and other AD-associated proteins (Grimes and Jope, 2001;
Hohman et al., 2014). Therefore, decreasing GSK-3β activity may
be potential for AD therapy (Engel et al., 2006; Gómez-Sintes et al.,
2011). Whether the inhibition of GSK-3βby IPP2A2 knockdown may
improve the cognition of the mice deserves further investigations.
Microtubule associated protein tau is a major cytoskeletal pro-
tein that regulates the dynamic structure and function of the
neurons. As a major protein component of the NFTs that is pos-
itively correlated with the dementia in AD patients (Avila et al.,
2002), and hyperphosphorylation of tau is a recognized factor
contributing to the memory deficits. The abnormally hyperphos-
phorylated tau impairs the axonal transport (Terwel et al., 2005;
Bertrand et al., 2013). In the present study, we also found that
knockdown IPP2A2 improved the dendrite complexity and spine
density, which may at least contribute to improved cognition.
Taken together, we have found in the present study that
downregulation of IPP2A2 not only restitutes PP2A activity but
also inhibits GSK-3β, which makes IPP2A2 a promising target to
arrest AD-like tau hyperphosphorylation, and restores dendrite
complexity and ameliorates cognitive deficits.
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